Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female~* At least 18 years old (inclusive)~* Weigh \>55 kg and have a body mass index (BMI) ≤38.0 kg/m2~* Diagnosed with PNH (white blood cell (WBC) clone \>10%)~* Lactose dehydrogenase (LD) ≥2 times the upper limit of normal~* Last transfusion within 12 months prior to screening~* Platelet count of \>30,000/mm3~* Absolute neutrophil count \>cells/500 µL~* Women of child-bearing potential (WOCBP) must have a negative pregnancy test at screening and must agree to use protocol defined methods of contraception for the duration of the study~* Males must agree to use protocol defined methods of contraception and agree to refrain from donating sperm for the duration of the study~* Able to provide documentary evidence of Neisseria meningitidis, Pneumococcal conjugate vaccine (multivalent) or Pneumococcal polysaccharide vaccine 23 (PCV13 or PPSV23) and Haemophilus influenzae Type B (Hib) vaccination within 2 years prior to Day 1 dosing, OR willing to receive vaccinations against Neisseria meningitidis at least two weeks prior to dosing on Day 1 with a booster on Day 57, and PCV13 and Hib vaccines at least two weeks prior to dosing on Day 1.~* Willing and able to give informed consent~Exclusion Criteria:~* Prior eculizumab (Soliris)® treatment~* Active bacterial infection~* Known infection with hepatitis B, hepatitis C or human immunodeficiency virus (HIV)~* Hereditary complement deficiency~* History of bone marrow transplantation~* Concurrent severe aplastic anemia (SAA), defined as currently receiving immunosuppressive therapy for SAA including but not limited to cyclosporin A, tacrolimus, mycophenolate mofetil or anti-thymocyte globulin.~* Participation in any other investigational drug trial or exposure to another investigational agent, device or procedure within 30 days~* Evidence of QTcF prolongation defined as \>450 ms for males and \>470 ms for females at screening~* Creatinine clearance (CrCl) \<50 mL/min (Cockcroft-Gault formula) at screening~* Breast-feeding women~* History of meningococcal disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): 180 mg pegcetacoplan/day
- Cohort 2 (Type: EXPERIMENTAL): 270 mg pegcetacoplan/day

Based on this trial design, predict the completion outcome and termination type (if applicable).